# US 2014/0235714 A1 · Cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0235714 A1
- Document ID: US20140235714A1
- Status: Published application
- Kind: A1
- Application number: 14/261,810
- Filed: 2014-04-25
- Published: 2014-08-21
- Earliest claimed: 2008-11-07
- Assignees: Triact Therapeutics, Inc.
- Applicants: TriAct Therapeutics, Inc.
- Inventors: Thomas F. WHITE; Edward F. SCHNIPPER; Dan HOTH
- Web page: https://patentgrep.com/patent/US20140235714A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/065: Diphenyl-substituted acyclic alcohols
- A61K 31/09: having two or more such linkages
- A61K 31/225: Polycarboxylic acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.

## Claims

### Claim 1

A method for treating a disease in a subject, wherein the subject has developed resistance to treatment with one or more tyrosine-kinase inhibitors, comprising administering an effective amount of a pharmaceutical compound capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGFR.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has developed resistance to one or more of an EGF-R inhibitor or an IGF-1R inhibitor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease is malignant, pre-malignant or benign cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer is selected from the group consisting of brain tumor, carcinoma, basalioma, basal cell carcinoma, teratoma, retinoblastoma, neuroblastoma, melanoma, choroidea melanoma, Dermatofibrosarcoma protuberans, Merkel cell carcinoma or Kaposi's sarcoma, seminoma, sarcoma, plasmocytoma, head and neck tumor, liver tumor, kidney tumor, renal cell tumor, squamous cell carcinoma, uterine tumor, endometrial tumor, bone tumor, prostate tumor, breast tumor, bladder tumor, pancreatic tumor, endometrium tumor, squamous cell carcinoma, stomach tumor, gliomas, glioblastoma multiforme, colorectal tumor, testicular tumor, colon tumor, rectal tumor, ovarian tumor, cervical tumor, eye tumor, central nervous system tumor, thyroid tumor, lung tumor, leukemia or lymphoma, multiple myeloma, skin tumor, a gynecologic tumor, Hodgkin's disease, cancer of the small intestine, cancer of the endocrine system, mesothelioma, cancer of the urethra, cancer of the penis, tumors related to Gorlin's syndrome, and tumor of unknown origin; and metastases thereto.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical compound comprises a catecholic butane of formula I, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, metabolites thereof, tautomers thereof or prodrugs thereof:
wherein R1 and R2 are independently H, lower alkyl, or lower acyl;
R3, R4, R5, R6, R10, R11, R12 and R13 are independently H or lower alkyl; and
R7, R8 and R9 are independently H, hydroxy, lower alkoxy or lower acyloxy.

### Claim 6 (depends on 5)

The method of claim 5, wherein the catecholic butane is selected from the group consisting of 1,4-bis(3,4-dihydroxphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dihydroxyphenyl)butane; 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropoxyphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-(3,4,5-trihydroxyphenyl)butane; 1,4-bis(3,4-diacetoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropionyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dibutyroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-divaleroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipivaloyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dineopentylcarboxylphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-phenylbutane; 1-(3,4-dihydroxyphenyl)-4-(2,5-dihydroxyphenyl)butane, nordihydroruaiaretic acid (NDGA), tetra-O-methyl NDGA; tetraglycinyl NDGA; tetra-dimethylglycinyl NDGA or a salt thereof; or tri-O-methyl NDGA; nordihydroguaiaretic acid tetrapivalate; nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein the catecholic butane is nordihydroguaiaretic acid.

### Claim 8

A method for treating cancer in a subject, wherein said subject has developed resistance to treatment with one or more tyrosine-kinase inhibitors, comprising administering an effective amount of a pharmaceutical composition capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGFR, wherein the pharmaceutical composition comprises a catecholic butane.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subject has developed resistance to one or more EGF-R inhibitors or IGF-1R inhibitors.

### Claim 10 (depends on 8)

The method of claim 8, wherein the cancer is selected from the group consisting of a solid tumor, lymphoma, leukemia, epithelial-based cancer, brain tumor, carcinoma, basalioma, basal cell carcinoma, teratoma, retinoblastoma, neuroblastoma, melanoma, choroidea melanoma, Dermatofibrosarcoma protuberans, Merkel cell carcinoma or Kaposi's sarcoma, seminoma, sarcoma, plasmocytoma, head and neck tumor, liver tumor, kidney tumor, renal cell tumor, squamous cell carcinoma, uterine tumor, endometrial tumor, bone tumor, prostate tumor, breast tumor, bladder tumor, pancreatic tumor, endometrium tumor, squamous cell carcinoma, stomach tumor, gliomas, glioblastoma multiforme, colorectal tumor, testicular tumor, colon tumor, rectal tumor, ovarian tumor, cervical tumor, eye tumor, central nervous system tumor, thyroid tumor, lung tumor, leukemia or lymphoma, multiple myeloma, skin tumor, a gynecologic tumor, Hodgkin's disease, cancer of the small intestine, cancer of the endocrine system, mesothelioma, cancer of the urethra, cancer of the penis, tumors related to Gorlin's syndrome, and tumor of unknown origin; and metastases thereto.

### Claim 11 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition comprises a catecholic butane of formula I, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, metabolites thereof, tautomers thereof or prodrugs thereof:
wherein R1 and R2 are independently H, lower alkyl, or lower acyl;
R3, R4, R5, R6, R10, R11, R12 and R13 are independently H or lower alkyl; and
R7, R8 and R9 are independently H, hydroxy, lower alkoxy or lower acyloxy.

### Claim 12 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition comprises a catecholic butane of formula II, pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof, metabolites thereof, tautomers thereof or prodrugs thereof:
wherein R5, R10, R6, and R13 are independently H;
when R3 is H, R11 is lower alkyl; or when R3 is lower alkyl, R11 is H;
when R4 is H, R12 is lower alkyl; or when R4 is lower alkyl, R12 is H;
two of R7, R8, and R9 are hydroxy, the other is H, and one of the hydroxy groups is in the 3-position and the other hydroxy group is in the 4-position relative to the alkylene substituent.

### Claim 13 (depends on 8)

The method of claim 8, wherein the catecholic butane is selected from the group consisting of 1,4-bis(3,4-dihydroxphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dihydroxyphenyl)butane; 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropoxyphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-(3,4,5-trihydroxyphenyl)butane; 1,4-bis(3,4-diacetoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropionyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dibutyroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-divaleroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipivaloyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dineopentylcarboxylphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-phenylbutane; 1-(3,4-dihydroxyphenyl)-4-(2,5-dihydroxyphenyl)butane, nordihydroruaiaretic acid (NDGA), tetra-O-methyl NDGA; tetraglycinyl NDGA; tetra-dimethylglycinyl NDGA or a salt thereof; or tri-O-methyl NDGA; nordihydroguaiaretic acid tetrapivalate; nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.

### Claim 14 (depends on 8)

The method of claim 8, wherein the catecholic butane is nordihydroguaiaretic acid.

### Claim 15 (depends on 8)

The method of claim 8, wherein the catecholic butane is administered in an amount selected from the group consisting of about 5 mg/kg to about 375 mg/kg per dose; about 5 mg/kg to about 250 mg/kg per dose; about 5 mg/kg to about 200 mg/kg per dose; about 5 mg/kg to about 150 mg/kg per dose; about 5 mg/kg to about 100 mg/kg per dose; about 5 mg/kg to about 75 mg/kg per dose; and about 5 mg/kg to about 50 mg/kg per dose.

### Claim 16 (depends on 8)

The method of claim 8, wherein the catecholic butane is administered in an amount selected from the group consisting of from about 1,500 mg per day to about 2,500 mg per day; from about 1,800 mg per day to about 2,300 mg per day; and about 2,000 mg per day.

### Claim 17 (depends on 8)

The method of claim 8, further comprising administering one or more additional anti cancer agents.

### Claim 18 (depends on 17)

The method of claim 17, wherein said one or more additional anti-cancer agents is selected from the group consisting of EGFR inhibitors, IGF-1R inhibitors, DNA damaging agents, Topoisomerase inhibitors and Mitotic inhibitors.

### Claim 19 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is administered more frequently than once every 6 days for a period of time, or more frequently than once every 2 days for a period of time.

### Claim 20

A method for determining a disease treatment, comprising:
(i) analyzing a sample obtained from a subject comprising measuring levels of IGF-1R and EGFR, and
(ii) comparing the levels of the IGF-1R and EGFR in the sample to the levels in a control;
wherein increased levels of IGF-1R, EGFR, or both as compared to the control indicate that the subject is to be treated with a dual tyrosine kinase inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the level of EGFR expression is at baseline levels or greater than baseline levels and where the level of IGF-1R expression is at baseline levels or greater than baseline levels.

### Claim 22 (depends on 21)

The method of claim 21, wherein the level of EGFR expression is at baseline levels and the level of IGF-1R expression is at 2× greater than baseline levels or more; the level of IGF-1R expression is at baseline levels and the level of EGFR expression is at 2× greater than baseline levels or more; or the level of IGF-1R expression is at 2× greater than baseline levels or more and the level of EGFR expression is at 2× greater than baseline levels or more.

### Claim 23 (depends on 20)

The method of claim 20, wherein the dual tyrosine kinase inhibitor is a catecholic butane.

### Claim 24 (depends on 23)

The method of claim 23, wherein the catecholic butane is selected from the group consisting of 1,4-bis(3,4-dihydroxphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dihydroxyphenyl)butane; 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropoxyphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-(3,4,5-trihydroxyphenyl)butane; 1,4-bis(3,4-diacetoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropionyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dibutyroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-divaleroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipivaloyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dineopentylcarboxylphenyl)-2,3-dimethylbutane; dihydroxyphenyl)-4-phenylbutane; 1-(3,4-dihydroxyphenyl)-4-(2,5-dihydroxyphenyl)butane, nordihydroguaiaretic acid (NDGA), tetra-O-methyl NDGA; tetraglycinyl NDGA; tetra-dimethylglycinyl NDGA or a salt thereof; or tri-O-methyl NDGA; nordihydroguaiaretic acid tetrapivalate; nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.

### Claim 25 (depends on 23)

The method of claim 23, wherein the catecholic butane is administered in an amount selected from the group consisting of about 5 mg/kg to about 375 mg/kg per dose; about 5 mg/kg to about 250 mg/kg per dose; about 5 mg/kg to about 200 mg/kg per dose; about 5 mg/kg to about 150 mg/kg per dose; about 5 mg/kg to about 100 mg/kg per dose; about 5 mg/kg to about 75 mg/kg per dose; and about 5 mg/kg to about 50 mg/kg per dose.

### Claim 26 (depends on 23)

The method of claim 23, wherein the catecholic butane is administered in an amount selected from the group consisting of from about 1,500 mg per day to about 2,500 mg per day; from about 1,800 mg per day to about 2,300 mg per day; and about 2,000 mg per day.

### Claim 27 (depends on 23)

The method of claim 23, wherein the catecholic butane is administered more frequently than once every 6 days for a period of time, or more frequently than once every 2 days for a period of time.

### Claim 28 (depends on 20)

The method of claim 20, further comprising administering one or more additional anti cancer agents.

### Claim 29 (depends on 28)

The method of claim 28, wherein said one or more additional anti-cancer agents is selected from the group consisting of EGFR inhibitors, IGF-1R inhibitors, DNA damaging agents, topoisomerase inhibitors and mitotic inhibitors.

### Claim 30

A method of selecting a subject for treatment with a dual tyrosine kinase inhibitor capable of inhibiting the tyrosine kinase activity of both IGF-1R and EGF-R, wherein said subject is identified as having levels of IGF-1R, EGFR, or both at baseline levels or at 2× greater than baseline levels as compared to control levels.

### Claim 31 (depends on 30)

The method of claim 30, wherein the level of EGFR expression is at baseline levels and the level of IGF-1R expression is at 2× greater than baseline levels or more; the level of IGF-1R expression is at baseline levels and the level of EGFR expression is at 2× greater than baseline levels or more; or the level of IGF-1R expression is at 2× greater than baseline levels or more and the level of EGFR expression is at 2× greater than baseline levels or more.

### Claim 32 (depends on 30)

The method of claim 30, wherein said subject is resistant to treatment with at least one tyrosine kinase inhibitor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subject has developed resistance to one or more EGF-R inhibitors or IGF-1R inhibitors.

### Claim 34 (depends on 30)

The method of claim 30, wherein the dual tyrosine kinase inhibitor is a catecholic butane.

### Claim 35 (depends on 34)

The method of claim 34, wherein the catecholic butane is selected from the group consisting of 1,4-bis(3,4-dihydroxphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dihydroxyphenyl)butane; 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropoxyphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-(3,4,5-trihydroxyphenyl)butane; 1,4-bis(3,4-diacetoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropionyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dibutyroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-divaleroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipivaloyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dineopentylcarboxylphenyl)-2,3-dimethylbutane; dihydroxyphenyl)-4-phenylbutane; 1-(3,4-dihydroxyphenyl)-4-(2,5-dihydroxyphenyl)butane, nordihydroguaiaretic acid (NDGA), tetra-O-methyl NDGA; tetraglycinyl NDGA; tetra-dimethylglycinyl NDGA or a salt thereof; or tri-O-methyl NDGA; nordihydroguaiaretic acid tetrapivalate; nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the catecholic butane is administered in an amount selected from the group consisting of about 5 mg/kg to about 375 mg/kg per dose; about 5 mg/kg to about 250 mg/kg per dose; about 5 mg/kg to about 200 mg/kg per dose; about 5 mg/kg to about 150 mg/kg per dose; about 5 mg/kg to about 100 mg/kg per dose; about 5 mg/kg to about 75 mg/kg per dose; and about 5 mg/kg to about 50 mg/kg per dose.

### Claim 37 (depends on 34)

The method of claim 34, wherein the catecholic butane is administered in an amount selected from the group consisting of from about 1,500 mg per day to about 2,500 mg per day; from about 1,800 mg per day to about 2,300 mg per day; and about 2,000 mg per day.

### Claim 38 (depends on 34)

The method of claim 34, wherein the catecholic butane is administered more frequently than once every 6 days for a period of time, or more frequently than once every 2 days for a period of time.

### Claim 39 (depends on 30)

The method of claim 30, further comprising administering one or more additional anti cancer agents.

### Claim 40 (depends on 39)

The method of claim 39, wherein said one or more additional anti-cancer agents is selected from the group consisting of EGFR inhibitors, IGF-1R inhibitors, DNA damaging agents, topoisomerase inhibitors and mitotic inhibitors.
